Reported total revenues of $9.9 million for Q1 2026, down from $26.5 million in Q1 2025. Net loss for the quarter was $18.9 million, compared to a $13.5 million loss in the prior year period. Operating loss widened to $18.5 million from $13.2 million in Q1 2025. Cash and cash equivalents increased to $33.7 million as of March 31, 2026, up from $10.2 million at year-end 2025. Entered into a definitive merger agreement with Garda Therapeutics for $21.80 per share in cash. Completed the divestiture of non-ROLVEDON assets to Cosette Pharmaceuticals for $35.0 million upfront plus potential earnouts.